Key facts
- It has raised $28.4M; the latest was Later Stage VC ($14.5M) in Mar 2026.
- Notable investors include CICC Capital, Legend Capital, OrbiMed, SDIC Unity Capital, BioTrack Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Sneuro Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Sneuro Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sneuro Medical
Developer of neuromodulation therapy technology and producer of nerve stimulation products designed for patients with chronic intractable pain. The company offers pain management and can effectively treat high-score and stubborn pain, its current product line under development includes source nerve implantable medical devices, spinal cord nerve stimulator SCS and short-term implantable peripheral nerve electrical stimulation PNS, which can provide more advanced and effective treatments for patients with pain, epilepsy, and heart failure, enabling its patients to relieve their pains and improve the quality of life.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2018
- Employees
- 6
- Website
- seeneuro.com/
- Ownership
- Privately Held (backing)
Sneuro Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sneuro Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sneuro Medical in its N-PORT filings yet. We sweep new filings monthly.